Skip to main content
Erschienen in: Journal of Community Health 6/2018

28.05.2018 | Original Paper

Assessing Disparities in the Rates of HCV Diagnoses Within American Indian or Alaska Native Populations Served by the U.S. Indian Health Service, 2005–2015

verfasst von: Brigg Reilley, Jessica Leston, Mona Doshani, Dana L. Haberling, Marissa Person, Thomas Weiser, Melissa Collier, Jonathan Iralu, Jorge Mera, Rick Haverkate

Erschienen in: Journal of Community Health | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Abstract

Hepatitis C virus (HCV) disproportionately affects American Indians/Alaska Natives (AI/AN). The Indian Health Service (IHS), via federal and tribal health facilities provides medical services to an estimated 2.2 million AI/AN people in the United States. HCV diagnoses, defined by International Classification of Diseases 9th Revision, Clinical Modification (ICD-9-CM) codes, were analyzed from 2005 to 2015. Results showed 29,803 patients with an HCV diagnosis; 53.4% were among persons born 1945–1965 and overall HCV burden was higher among males than females. These data will help inform local, regional, and national efforts to address, plan for and carry out a national strategy to provide treatment for HCV infected patients and programs to prevent new HCV infections.
Literatur
1.
Zurück zum Zitat Centers for Disease Control and Prevention. (2012). Recommendations for the Identification of chronic hepatitis C virus infection among persons born during 1945–1965. Morbidity and Mortality Weekly Report, 61(RR04), 1–18. Centers for Disease Control and Prevention. (2012). Recommendations for the Identification of chronic hepatitis C virus infection among persons born during 1945–1965. Morbidity and Mortality Weekly Report, 61(RR04), 1–18.
3.
Zurück zum Zitat Gordon, S., Lamerato, L., Rupp, L., Holmberg, S. D., Moorman, A. C., Spradling, P. R., et al. (2015). Prevalence of cirrhosis in hepatitis C patients in the Chronic Hepatitis Cohort Study (CHECS): A Retrospective and Prospective Observational Study. The American Journal of Gastroenterology, 110, 1169–1177.CrossRef Gordon, S., Lamerato, L., Rupp, L., Holmberg, S. D., Moorman, A. C., Spradling, P. R., et al. (2015). Prevalence of cirrhosis in hepatitis C patients in the Chronic Hepatitis Cohort Study (CHECS): A Retrospective and Prospective Observational Study. The American Journal of Gastroenterology, 110, 1169–1177.CrossRef
4.
Zurück zum Zitat Ly, K. N., Hughes, E. M., Jiles, R. B., & Holmberg, S. D. (2016). Rising mortality associated with hepatitis C virus in the United States, 2003–2013. Clinical Infectious Diseases, 62(10), 1287–1288.CrossRef Ly, K. N., Hughes, E. M., Jiles, R. B., & Holmberg, S. D. (2016). Rising mortality associated with hepatitis C virus in the United States, 2003–2013. Clinical Infectious Diseases, 62(10), 1287–1288.CrossRef
7.
Zurück zum Zitat Edlin, B., Eckhardt, B., Shu, M., Holmberg, S. D., & Swan, T. (2016). Toward a more accurate estimate of the prevalence of hepatitis C in the United States. Hepatology, 62(5), 1353–1363.CrossRef Edlin, B., Eckhardt, B., Shu, M., Holmberg, S. D., & Swan, T. (2016). Toward a more accurate estimate of the prevalence of hepatitis C in the United States. Hepatology, 62(5), 1353–1363.CrossRef
8.
Zurück zum Zitat Van der Meer, A., Veldt, B., Feld, J., Wedemeyer, H., Dufour, J. F., Lammert, F., et al. (2012). Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA, 308(24), 2584–2593.CrossRef Van der Meer, A., Veldt, B., Feld, J., Wedemeyer, H., Dufour, J. F., Lammert, F., et al. (2012). Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA, 308(24), 2584–2593.CrossRef
9.
Zurück zum Zitat Bruno, S., Di Marco, V., Iavarone, M., Roffi, L., Crosignani, A., Calvaruso, V., et al. (2016). Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population. Journal of Hepatology, 64(6), 1217–1223.CrossRef Bruno, S., Di Marco, V., Iavarone, M., Roffi, L., Crosignani, A., Calvaruso, V., et al. (2016). Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population. Journal of Hepatology, 64(6), 1217–1223.CrossRef
11.
Zurück zum Zitat Reilley, B., Leston, J., Hariri, S., et al. (2016). Birth cohort testing for hepatitis C virus—Indian Health Service 2012–2015. Morbidity and Mortality Weekly Report,, 65, 467–469.CrossRef Reilley, B., Leston, J., Hariri, S., et al. (2016). Birth cohort testing for hepatitis C virus—Indian Health Service 2012–2015. Morbidity and Mortality Weekly Report,, 65, 467–469.CrossRef
12.
Zurück zum Zitat Ward, J., & Mermin, J. (2015). Simple, effective, but out of reach? Public health implications of HCV drugs. The New England Journal of Medicine, 373, 2678–2680.CrossRef Ward, J., & Mermin, J. (2015). Simple, effective, but out of reach? Public health implications of HCV drugs. The New England Journal of Medicine, 373, 2678–2680.CrossRef
14.
Zurück zum Zitat Moon, A., Green, P., Berry, K., & Ioannou, G. N. (2017). Transformation of hepatitis C antiviral treatment in a national healthcare system following the introduction of direct antiviral agents. Alimentary Pharmacology & Therapeutics, 45(9), 1201–1212.CrossRef Moon, A., Green, P., Berry, K., & Ioannou, G. N. (2017). Transformation of hepatitis C antiviral treatment in a national healthcare system following the introduction of direct antiviral agents. Alimentary Pharmacology & Therapeutics, 45(9), 1201–1212.CrossRef
15.
Zurück zum Zitat McMahon, B. J., Bruden, D., Townshend-Bulson, L., Simons, B., Spradling, P., Livingston, S., et al. (2017). Infection with hepatitis C virus genotype 3 is an independent risk factor for end-stage liver disease, hepatocellular carcinoma, and liver-related death. Clinical Gastroenterology and Hepatology, 15, 431–437.e2.CrossRef McMahon, B. J., Bruden, D., Townshend-Bulson, L., Simons, B., Spradling, P., Livingston, S., et al. (2017). Infection with hepatitis C virus genotype 3 is an independent risk factor for end-stage liver disease, hepatocellular carcinoma, and liver-related death. Clinical Gastroenterology and Hepatology, 15, 431–437.e2.CrossRef
Metadaten
Titel
Assessing Disparities in the Rates of HCV Diagnoses Within American Indian or Alaska Native Populations Served by the U.S. Indian Health Service, 2005–2015
verfasst von
Brigg Reilley
Jessica Leston
Mona Doshani
Dana L. Haberling
Marissa Person
Thomas Weiser
Melissa Collier
Jonathan Iralu
Jorge Mera
Rick Haverkate
Publikationsdatum
28.05.2018
Verlag
Springer US
Erschienen in
Journal of Community Health / Ausgabe 6/2018
Print ISSN: 0094-5145
Elektronische ISSN: 1573-3610
DOI
https://doi.org/10.1007/s10900-018-0528-7

Weitere Artikel der Ausgabe 6/2018

Journal of Community Health 6/2018 Zur Ausgabe